Literature DB >> 15479866

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

D E Furst1, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15479866      PMCID： PMC1766772          DOI： 10.1136/ard.2004.029272

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  112 in total

1.  Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Authors:  Jong-Hoon Lee; Nancy R Slifman; Sharon K Gershon; Evelyne T Edwards; William D Schwieterman; Jeffrey N Siegel; Robert P Wise; S Lori Brown; John N Udall; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-10

2.  Treatment with infliximab for a child with Behçet's disease.

Authors:  Frank T Saulsbury; James A Mann
Journal:  Arthritis Rheum       Date:  2003-08-15

3.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07

4.  Infliximab in the treatment of refractory posterior uveitis.

Authors:  Annie Joseph; Dev Raj; Harminder S Dua; Pauline T Powell; Peter C Lanyon; Richard J Powell
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

5.  Efficacy of infliximab in resistant psoriatic arthritis.

Authors:  Carlo Salvarani; Fabrizio Cantini; Ignazio Olivieri; Pierluigi Macchioni; Angela Padula; Laura Niccoli; Maria Grazia Catanoso; Giovanni Lo Scocco; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2003-08-15

6.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.

Authors:  James P Utz; Andrew H Limper; Sanjay Kalra; Ulrich Specks; John P Scott; Zvezdana Vuk-Pavlovic; Darrell R Schroeder
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

Review 7.  Adalimumab (HUMIRA): a review.

Authors:  Noah Scheinfeld
Journal:  J Drugs Dermatol       Date:  2003-08       Impact factor: 2.114

8.  Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

Authors:  Alice B Gottlieb; Umesh Chaudhari; Lisa D Mulcahy; Shu Li; Lisa T Dooley; Daniel G Baker
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

Review 9.  Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Authors:  Hyon J Kwon; Timothy R Coté; Michael S Cuffe; Judith M Kramer; M Miles Braun
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391

10.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors:  J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2003-06
View more
  16 in total

Review 1.  Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.

Authors:  Silja Rott; Ulrich Mrowietz
Journal:  BMJ       Date:  2005-03-26

2.  [Position on choice of agents among TNF inhibitors].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 3.  TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Authors:  Sonja Merkesdal; Henning Zeidler
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

Review 4.  Treatment of rheumatoid arthritis.

Authors:  Paul Emery
Journal:  BMJ       Date:  2006-01-21

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 6.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 7.  [Rheumatology].

Authors:  H U Scherer; G R Burmester
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

Review 8.  Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Authors:  Vivianne Malmström; Christina Trollmo; Lars Klareskog
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

Review 9.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

10.  The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes.

Authors:  Dong-Hwan Kim; Jason T Smith; Ashutosh Chilkoti; William M Reichert
Journal:  Biomaterials       Date:  2007-04-12       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.